VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin thera ...
As of July 31, 2025, the objective response rate (ORR) was 90% in NTRK fusion patients, as assessed by the Independent Review Committee (IRC). Among the patients who completed full efficacy ...
Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEsDemonstrated selective T cell cytotoxicity against cells ...
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that results from the Phase III ...
Pilatus Biosciences, a biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced the Company will present new preclinical ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators, including the Company’s ...
Highlights of the rese-cel clinical and translational data being presented at ACR Convergence 2025 as of the data cut-off date of September 11, 2025, and development updates include: ...
Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically ...
Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...
Opinion
6dOpinion
Despite naysayers and rising costs, data shows that college still pays off for students – and society overall
An estimated 18.4 million workers with a college degree in the U.S. will retire from now through 2032, according to Georgetown University’s Center on Education and the Workforce. This is far greater ...
Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback